HighTower Advisors’s AbbVie ABBV Stock Holding History

HighTower Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100	Closed	-$180	–	3801
2024 Q3	$180	Buy	+100	New	+$18.7K	﹤0.01%	3708
2022 Q1	–	Sell	-15	Closed	-$67K	–	3394
2021 Q4	$67K	Sell	15 -785	-98%	-$92.7K	﹤0.01%	2991
2021 Q3	$1K	Buy	+800	New	+$91.4K	﹤0.01%	3108
2016 Q2	–	Sell	-40,100	Closed	-$66.2M	–	1760
2016 Q1	$66.2M	Buy	+40,100	New	+$2.24M	0.22%	22

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighTower Advisors's ABBV Position: Q1 2026 in Review

HighTower Advisors increased its AbbVie (ABBV) stake by 1.8% in Q1 2026, buying an estimated $6.46M and bringing the position to 1,658,024 shares worth $361M. The position accounts for 0.38% of the portfolio, ranked #46.

HighTower Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $380M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

HighTower Advisors held 1,658,024 shares of AbbVie worth $361M as of Q1 2026.
HighTower Advisors bought 29,113 AbbVie shares in Q1 2026, an estimated $6.46M.
AbbVie made up 0.38% of HighTower Advisors's portfolio in Q1 2026, its #46 holding.
HighTower Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
HighTower Advisors's AbbVie position peaked at $380M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.